Pay in 4 interest-free payments of $12.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
It is clinically tested for its role in the treatment of left ventricular systolic heart failure
WAY-316606 can increase total bone area in a murine calvarial organ culture assay
SKLB-610 inhibited angiogenesis-related tyrosine kinase VEGFR2
5-3(6)1-2-4(7)8/h2-9
and good permeability in the Caco-2 cell assay
Ledipasvir - CAS# 1256388-51-8 0153 It is clinically tested forLedipasvir, also known as GS 5885, CAS No. 1256388 51 8, is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg sofosbuvir 400 mg (trade name Harvoni). The ledipasvir sofosbuvir combination is a direct acting antiviral agent that interferes with HCV replication and can be used to treat